<DOC>
	<DOCNO>NCT01931488</DOCNO>
	<brief_summary>The Feasibility Novel 124I-MIBG Tracer Evaluation Myocardial Sympathetic Denervation Assessment Neuroendocrine tumor . Comparison 123I-MIBG .</brief_summary>
	<brief_title>124I-MIBG Tracer Evaluation Myocardial Sympathetic Denervation Assessment Neuroendocrine Tumors .</brief_title>
	<detailed_description>The autonomic nervous system consist sympathetic parasympathetic innervation . The neurotransmitter sympathetic system norepinephrine ( NE ) response stimulus , release synaptic space Guanethidine false neurotransmitter analog NE catabolize . When labeled radioactive iodine radiotracer meta-iodobenzylguanidine ( I-MIBG ) may use localization different clinical pathological condition . There two main indication scintigrpahy label MIBG 1 . Whole body image neuroendocrine tumor phechromocytoma neuroblastoma . Scintigraphy allow stag disease well follow patient MIBG-avid tumor . Moreover , label high dos 131I used treatment patient metastatic neuroendocrine tumor . 2. indication label MIBG scintigraphy assessment myocardial sympathetic nerve ending Autonomic disturbance common symptom Parkinson disease ( PD ) . They may appear early disease occasionally prior motor symptom , thus raise potential use autonomic system assessment biological marker prediction future development motor PD . Labeled MIBG image potential test determine integrity individual autonomic function . Reduced MIBG uptake indicate postganglionic sympathetic dysfunction , observe early stage PD . MIBG scintigraphy think sensitive modality diagnosis PD , assist differential diagnosis parkinsonian disease , PD movement disorder . This method also report high specificity . The labeled MIBG use routinely tracer label 123I use gamma camera performance planar image 3D SPECT image . 123I emits predominantly γ photon energy 159 keV half-life 13.2 hour . Quantitation 123I MIBG myocardial uptake Heart to-Mediastinum ratio ( H/M ) measure planar imaging find predictive value assessment prognosis cardiac event . H/M obtain 123I MIBG SPECT report improve differentiation subject normal abnormal MIBG uptake . Unlike 123I gamma emit isotope 124I , positron emitter , half-life 4.2 , use positron emission tomography ( PET ) thus allow good well quantification tracer accumulation Studies use 124I-MIBG positron emission tomography initiate early 1992 . Preliminary study demonstrate image 124I-MIBG human safe use correct amount radioactivity tracer . In study propose perform two image session . First would injection 6mCi 123I-MIBG result radiation dose 4.2 mSv.In second session 0.8 mCi 124I-MIBG injected result radiation dose 7.4 mSv . The estimated total radiation dose patient study 11.8 mSv . When compare radiation dos daily routine scintigraphy : The radiation dose bone scan ( 25 mCi Tc MDP ) 5.3 mSv . The radiation dose 12 mCi 18F-FDG PET-CT 13.32 mSv . Trail Objectives Given merit MIBG ligand 124I positron emission tomography , purpose study evaluate add value PET-CT 124I-MIBG tracer , compare planar SPECT image routine 123I-MIBG tracer 1 . Assessment Myocardial Sympathetic Denervation patient Parkinson family member patienst PD carrier mulation PD . 2 . Staging follow-up pt . neuroendocrine malignancy .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Age ≥ 18 Signed Informed Consent Patients diagnose Parkinson disease Patients histologically confirm neuroendocrine tumor Age &lt; 18 Any cardiovascular disease Taking medication influence sympathetic system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>